- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 11.06. | Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 1 | GlobeNewswire (USA) | ||
| 03.06. | H.C. Wainwright bestätigt Kaufempfehlung für Zenas Biopharma nach Studienerfolg | 3 | Investing.com Deutsch | ||
| 03.06. | H.C. Wainwright reiterates Zenas Biopharma stock rating at buy | 1 | Investing.com | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 03.06. | Zenas BioPharma reports positive phase 3 trial results for obexelimab | 2 | Investing.com | ||
| 03.06. | Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | 2 | GlobeNewswire (USA) | ||
| 28.05. | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | 370 | GlobeNewswire (Europe) | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen | |
| 19.05. | Zenas BioPharma präsentiert Studiendaten zu Obexelimab auf dem EULAR-Kongress | 1 | Investing.com Deutsch | ||
| 19.05. | Zenas BioPharma to present obexelimab trial data at EULAR congress | 3 | Investing.com | ||
| 19.05. | Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | 227 | GlobeNewswire (Europe) | - Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT - WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 18.05. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 13.05. | Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor | 204 | GlobeNewswire (Europe) | - Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - -... ► Artikel lesen | |
| 13.05. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Zenas BioPharma GAAP EPS of -$1.46 beats by $0.22 | 2 | Seeking Alpha | ||
| 13.05. | Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | 511 | GlobeNewswire (Europe) | - Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results - - Obexelimab... ► Artikel lesen | |
| 30.04. | Zenas BioPharma rises as CEO continues insider purchases | 1 | Seeking Alpha | ||
| 17.04. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 31.03. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Zenas BioPharma Prices $300M Capital Raise in Dual Offering | 4 | Seeking Alpha |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,220 | -1,20 % | VALNEVA SE: Valneva Announces Successful Outcome of its Annual General Meeting | Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that... ► Artikel lesen | |
| AMGEN | 315,60 | +1,72 % | Amgen - AMGN: Pharma-Aktie mit Cup & Handle! | Fliegt der Deckel bald weg? Kursziel Allzeithoch! Amgen (AMGN) erhöht Dividenden seit 2011! Dividendenrendite 2025: 2.91 Prozent! Amgen (AMGN) - US0311621009 Rückblick: Bei dem schwachen US-Gesamtmarkt... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 556,10 | +2,04 % | Regeneron Pharmaceuticals, Inc.: Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG) | Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target... ► Artikel lesen | |
| VIVOSIM LABS | 1,070 | 0,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,075 | +1,90 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,300 | -2,03 % | Stifel reiterates Hold on BioMarin stock, keeps $68 price target | ||
| SAREPTA THERAPEUTICS | 14,140 | +0,28 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart Publishes Presentation Urging Shareholders to Vote "FOR" ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY | ||
| ARROWHEAD PHARMACEUTICALS | 70,92 | +1,75 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) | REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and... ► Artikel lesen | |
| XOMA ROYALTY | 37,400 | +0,54 % | XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date | EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash... ► Artikel lesen | |
| TRAWS PHARMA | 0,850 | +2,16 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| UNIQURE | 41,550 | -3,82 % | uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares | LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| ZAI LAB LTD ADR | 16,100 | -1,23 % | ZAI LAB (09688): NEXT DAY DISCLOSURE RETURN | ||
| TRINITY BIOTECH | 0,361 | +3,35 % | Trinity Biotech plc: Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market | - New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-performance... ► Artikel lesen | |
| VERASTEM | 3,050 | +0,69 % | RBC Kapital bestätigt Rating für Verastem: G12D-Inhibitor mit über 250 % Kurspotenzial |
Das Unternehmen ZENAS BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,24 % bei einem Aktienkurs von 24,730 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.